Analyst rates Exagen (XGN) stock a Hold, as Q3 revenue grew 7% year over year but fell 8% sequentially.
Exagen Inc (XGN) posted its best-ever third quarter with $18.4 million in revenue, record $451 ASP, and 85% Pharma Services growth, while teeing up its highly anticipated myositis test for early 2027.
Detailed price information for Exagen Inc (XGN-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.